BIONURE
Contact
Albert G. Zamora. CEO
Address: C/ Dalmases 27, Local 1
City: 08017 Barcelona
Province: Barcelona
Phone: 34 931258607
info@bionure.com
http://www.bionure.com
Mission and Objectives
Bionure is an early-stage drug development company founded in 2009 (spin-off from Hospital Clínic de Barcelona - IDIBAPS and CSIC) based in Barcelona and San Jose, California. We are aimed at developing neuroprotective therapies for the treatment of neurodegenerative diseases, with special focus in Multiple Sclerosis (MS), Acute Optic Neuritis (AON) and Glaucoma (GL).
Products/Services, Areas of interest for future collaborations/Alliances
Neurodegenerative diseases are sanitary priority in advanced countries because of its high frequency, social and sanitary costs and the lack of curative therapies.
Available treatments for MS are immunomodulatory drugs, only partially effective and have many side effects.
In particular, current treatments for MS are immunomodulatory drugs (modulate the body immune system) that decrease the frequency of relapses and hold up its progression, but they are only partially effective and have many side effects. In the case of AON, the treatment with corticosteroids is barely effective.
In the case of GL, current marketed drugs are IOP-lowering drugs (only reduce intraocular pressure).
In these diseases, there are many patients who don't benefit from current therapies.
Bionure develops BN201, a small molecule, First-in-Class, neuroprotective drug. It represents a new approach for the treatment of MS, AON and GL, since there is not any neuroprotective drug in the market.
The aim of Bionure is to complete the clinical development of BN201 until Phase IIa (PoC of neuroprotection in humans) asap and close co-development/licensing agreements with other pharmaceutical companies.
The short-term strategy is to develop an i.v BN201 for the treatment of AON. This will allow to complete PhIIa in humans sooner (PoC of neuroprotection). There's also the possibility to obtain Orphan Drug Designation. Finally, BN201 will be extended to bigger indications such as MS and GL.
BN201 is in preclinical development (IND<1 year, to be completed during 2013). Clinical trials are expected to be started at the end of 2013 - earlier 2014 and PhIIa to be completed by 2016.
Permalink  

 
BIONURE
Developed by Web4Bio